NEW YORK, July 17, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual property protection around its lead product candidate, AMR-001, with the notice of the issuance of patent number 2011127184 in Russia. This patent is in the family titled "Compositions and Methods of Vascular Injury Repair" and protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction ("AMI").
NeoStem Announces Geographic Expansion Of Intellectual Property Coverage Of AMR-001 To Russia
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts